trending Market Intelligence /marketintelligence/en/news-insights/trending/P-bGaAPQvIT1SLcqYR_Gjw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In this list

FDA Watch: Approvals for J&J, Roche; designations for Regeneron, Sanofi

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


FDA Watch: Approvals for J&J, Roche; designations for Regeneron, Sanofi

Approvals and designations made by the U.S. Food and Drug Administration for the week ended March 8.

Approvals

* Johnson & Johnson's Spravato, an esketamine nasal spray for treatment-resistant depression. The medicine — derived from ketamine, a known club drug — will be offered through a restricted distribution system due to its potential for abuse.

* Roche Holding AG's combination of Tecentriq and Celgene Corp.'s chemotherapy drug Abraxane for triple-negative breast cancer patients, whose disease has worsened or has spread to other parts of the body and expresses PD-L1.

SNL Image
FDA headquarters in Silver Spring, Md.
Source: Associated Press

Priority review

* Regeneron Pharmaceuticals Inc. and Sanofi's Dupixent as an add-on maintenance treatment for adults with inadequately controlled severe chronic rhinosinusitis with nasal polyps.

* Eli Lilly and Co.'s Emgality to prevent episodic cluster headaches in adults. Emgality was previously approved to prevent migraine in adults.

* Celgene Corp.'s fedratinib for myelofibrosis.

Other designations

* Orphan drug, for Celgene's fedratinib, for secondary and primary myelofibrosis.

* Orphan drug, for Acceleron Pharma Inc.'s ACE-083, for Charcot-Marie-Tooth disease.

* Rare pediatric disease, for Inventiva SA's odiparcil, for mucopolysaccharidosis VI, also known as Maroteaux-Lamy syndrome.